{"nctId":"NCT01292473","briefTitle":"A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)","startDateStruct":{"date":"2011-03"},"conditions":["Chronic Idiopathic Urticaria"],"count":323,"armGroups":[{"label":"Placebo","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo","Drug: Omalizumab"]},{"label":"Omalizumab 75 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Omalizumab"]},{"label":"Omalizumab 150 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Omalizumab"]},{"label":"Omalizumab 300 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Omalizumab"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Omalizumab","otherNames":["Xolair"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) CIU/CSU refractory to H1 antihistamines at the time of randomization.\n\nExclusion Criteria:\n\n* Treatment with an investigational agent within 30 days prior to screening.\n* Weight \\< 20 kg (44 lbs).\n* Clearly defined underlying etiology for chronic urticarias other than CIU.\n* Evidence of parasitic infection.\n* Atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus, or other skin disease associated with itch.\n* Previous treatment with omalizumab within a year prior to screening.\n* Routine doses of the following medications within 30 days prior to screening: Systemic or cutaneous (topical) corticosteroids (prescription or over the counter), hydroxychloroquine, methotrexate, cyclosporine, or cyclophosphamide.\n* Intravenous (IV) immunoglobulin G (IVIG), or plasmapheresis within 30 days prior to screening.\n* Regular (daily/every other day) doxepin (oral) use within 6 weeks prior to screening.\n* Any H2 antihistamine use within 7 days prior to screening.\n* Any leukotriene receptor antagonist (LTRA) (montelukast or zafirlukast) within 7 days prior to screening.\n* Any H1 antihistamines at greater than approved doses within 3 days prior to screening.\n* Patients with current malignancy, history of malignancy, or currently under work-up for suspected malignancy except non-melanoma skin cancer that has been treated or excised and is considered resolved.\n* Hypersensitivity to omalizumab or any component of the formulation.\n* History of anaphylactic shock.\n* Presence of clinically significant cardiovascular, neurological, psychiatric, metabolic, or other pathological conditions that could interfere with the interpretation of the study results and or compromise the safety of the patients.\n* Evidence of current drug or alcohol abuse.\n* Nursing women or women of childbearing potential, unless they meet the following definition of post-menopausal: 12 months of natural amenorrhea or 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) levels \\> 40 milli-international units per milliliter (mIU/mL) or 6 weeks post surgical bilateral oophorectomy (with or without hysterectomy) or hysterectomy or are using one or more of the following acceptable methods of contraception: surgical sterilization, hormonal contraception, and double-barrier methods.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","maximumAge":"75 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in the Weekly Itch Severity Score at Week 12","description":"The weekly itch severity score is the sum of the daily itch severity scores over 7 days and ranges from 0 to 21. The daily itch severity score is the average of the morning and evening scores on a scale of 0 (none) to 3 (severe). The Baseline weekly itch severity score is the sum of the daily itch severity scores over the 7 days prior to the first treatment. A higher itch severity score indicates more severe itching. A negative change score indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.14","spread":"5.58"},{"groupId":"OG001","value":"-5.87","spread":"6.45"},{"groupId":"OG002","value":"-8.14","spread":"6.44"},{"groupId":"OG003","value":"-9.77","spread":"5.95"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Weekly Urticaria Activity Score (UAS7) at Week 12","description":"The urticaria activity score (UAS) is a composite of scores on a scale of 0 (none) to 3 (intense/severe) for 1) the number of wheals (hives); and 2) the intensity of the itch, measured twice daily (morning and evening). Daily UAS is the average of morning and evening scores (ranging from 0-6) and the UAS7 is the sum of the daily UAS over 7 days (ranging from 0-42). Baseline UAS7 is calculated using data from the 7 days prior to the first treatment date. A higher UAS indicates more urticaria activity. A negative change score indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.36","spread":"11.61"},{"groupId":"OG001","value":"-13.08","spread":"12.67"},{"groupId":"OG002","value":"-17.89","spread":"13.23"},{"groupId":"OG003","value":"-21.74","spread":"12.78"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Weekly Number of Hives Score at Week 12","description":"The weekly hives score is the sum of the daily hives scores over 7 days and ranges from 0 to 21. The number of hives is measured twice daily (morning and evening) on a scale of 0 (none) to 3 (\\> 12 hives per 12 hours). The daily hives score is the average of the morning and evening scores. The Baseline score is the sum of the daily hives scores over the 7 days prior to the first treatment. A higher score indicates more hives. A negative change score indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.22","spread":"6.56"},{"groupId":"OG001","value":"-7.21","spread":"6.96"},{"groupId":"OG002","value":"-9.75","spread":"7.28"},{"groupId":"OG003","value":"-11.97","spread":"7.58"}]}]}]},{"type":"SECONDARY","title":"Time to Minimally Important Difference (MID) Response in the Weekly Itch Severity Score by Week 12","description":"The weekly itch severity score is the sum of the daily itch severity scores over 7 days and ranges from 0 to 21. The daily itch severity score is the average of the morning and evening scores on a scale of 0 (none) to 3 (severe). The Baseline weekly itch severity score is the sum of the daily itch severity scores over the 7 days prior to the first treatment. A higher itch severity score indicates more severe itching. A negative change score indicates improvement.\n\nThe MID response for weekly itch severity score was defined as a reduction from baseline in weekly itch severity score of 5 points or more. The time to weekly itch severity score MID response was defined as the time (in weeks) from Day 1 to the study week when weekly itch severity score MID response was first achieved.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":null},{"groupId":"OG001","value":"2.0","spread":null},{"groupId":"OG002","value":"2.0","spread":null},{"groupId":"OG003","value":"1.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a UAS7 Less Than or Equal to 6 at Week 12","description":"The urticaria activity score (UAS) is a composite of scores on a scale of 0 (none) to 3 (intense/severe) for 1) the number of wheals (hives); and 2) the intensity of the itch, measured twice daily (morning and evening). Daily UAS is the average of morning and evening scores (ranging from 0-6) and the UAS7 is the sum of the daily UAS over 7 days (ranging from 0-42). Baseline UAS7 is calculated using data from the 7 days prior to the first treatment date. A higher UAS indicates more urticaria activity. A negative change score indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.0","spread":null},{"groupId":"OG001","value":"26.8","spread":null},{"groupId":"OG002","value":"42.7","spread":null},{"groupId":"OG003","value":"65.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Weekly Itch Severity Score MID Responders at Week 12","description":"The weekly itch severity score is the sum of the daily itch severity scores over 7 days and ranges from 0 to 21. The daily itch severity score is the average of the morning and evening scores on a scale of 0 (none) to 3 (severe). The Baseline weekly itch severity score is the sum of the daily itch severity scores over the 7 days prior to the first treatment. A higher itch severity score indicates more severe itching. A negative change score indicates improvement.\n\nThe MID response for weekly itch severity score was defined as a reduction from baseline in weekly itch severity score of 5 points or more. This outcome measure shows the percentage of participants classified as MID Responders at Week 12, meaning their weekly itch severity scores at Week 12 were at least 5 points lower than at Baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.1","spread":null},{"groupId":"OG001","value":"56.1","spread":null},{"groupId":"OG002","value":"69.5","spread":null},{"groupId":"OG003","value":"78.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Weekly Size of the Largest Hive Score at Week 12","description":"The size of the largest hive is assessed twice daily (morning and evening) on a scale of 0 (none) to 3 (\\> 2.5 cm). The daily score is the average of the morning and evening scores. The weekly size of the largest hive score is the sum of the daily scores over 7 days, and ranges from 0 to 21. The Baseline weekly size of the largest hive score is the sum of daily scores over the 7 days prior to the first treatment. A higher score indicates larger hives. A negative change score indicates a reduction in hive size.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.04","spread":"5.55"},{"groupId":"OG001","value":"-6.52","spread":"6.33"},{"groupId":"OG002","value":"-7.84","spread":"6.75"},{"groupId":"OG003","value":"-11.00","spread":"7.18"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Overall Dermatology Life Quality Index (DLQI) at Week 12","description":"The dermatology life quality index (DLQI) is a 10-item dermatology-specific health-related quality of life measure. Participants rate their dermatology symptoms as well as the impact of their skin condition on various aspects of their lives on a scale of 0 (Not at all) to 3 (Very much). The overall DLQI is the sum of the responses to the 10 items and ranges from 0 to 30. A lower score indicates a better quality of life. A negative change score indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.09","spread":"7.47"},{"groupId":"OG001","value":"-7.50","spread":"7.16"},{"groupId":"OG002","value":"-8.29","spread":"6.31"},{"groupId":"OG003","value":"-10.15","spread":"6.83"}]}]}]},{"type":"SECONDARY","title":"Percentage of Angioedema-free Days From Week 4 to Week 12","description":"The percentage of angioedema-free days from Weeks 4 to 12 was defined as the number of days a patient reported as angioedema-free in the daily diary divided by the total number of days with a non-missing diary entry, starting at the Week 4 visit and ending the day prior to the Week 12 visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.2","spread":"19.0"},{"groupId":"OG001","value":"93.5","spread":"14.9"},{"groupId":"OG002","value":"91.6","spread":"17.4"},{"groupId":"OG003","value":"95.5","spread":"14.5"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":79},"commonTop":["Nasopharyngitis","Headache","Idiopathic urticaria","Upper respiratory tract infection","Influenza"]}}}